APR 2.3 2007 8

PTO/SB/26 (09-06)
Approved for use through 03/31/2007. OMB 0651-0231
U.S. Patent and Trademark Office, U.S. DEPARTMENT O.OMBERCE
sperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

Docket Number (Optional)

REJECTION OVER A "PRIO	R" PATENT	C0989.70016US00
In re Application of: Eugene Y. Chan		
Application No.: 09/852,968-Conf. #5672		
Filed: May 10, 2001		
For: METHODS AND PRODUCTS FOR AN	ALYZING POLYMERS	
The owner*, U.S. Genomic Instant application hereby disclaims, except as provided trinstant application which would extend beyond the expiration as the term of said prior patent is defined in 35 U.S.C. 15 by any terminal disclaimer. The owner hereby agrees the only for and during such period that it and the prior pate on the instant application and is binding upon the grantee.	below, the terminal part of the statutory on date of the full statutory term of prior 54 and 173, and as the term of said p at any patent so granted on the instar ont are commonly owned. This agreer	r term of any patent granted on the patent No. 6,403,311  rlor patent is presently shortenent application shall be enforceable
In making the above disclaimer, the owner does not dis- application that would extend to the expiration date of the patent, "as the term of said prior patent is presently sheater."	claim the terminal part of the term of ne full statutory term as defined in 35	U.S.C. 154 and 173 of the price
expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaim has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of it		ened by any terminal disclaimer.
Check either box 1 or 2 below, if appropriate.		
For submissions on behalf of a business/orga etc.), the undersigned is empowered to act on		, university, government agency,
I hereby declare that all statements made herein of n and belief are believed to be true; and further that these and the like so made are punishable by fine or imprisonr and that such willful false statements may jeopardize the	statements were made with the known ment, or both, under Section 1001 of	rledge that willful false statement Fitle 18 of the United States Cod
2. The undersigned is an attorney or agent of red	cord. Reg. No.	
Signati	ure	Date
EBRAHT 00000033 232825 09852968	John J. Canepa Chief Executive Officer U.S. Genomics, Inc.	
65.00 DA	Typed or printed name	
	-	(781) 937-5550 Telephone Number
X Terminal disclaimer fee under 37 CFR 1.20(d) is	included	,
*Statement under 37 CFR 1.20(g) is  *Statement under 37 CFR 3.73(b) is required if to Form PTO/SB/96 may be used for making this of	erminal disclaimer is signed by the ass	signee (owner).
Certificate of	Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to a the date shown below with sufficient postage as First Class Mail, Alexandria, VA 22313-1450.	is being attached or enclosed) is being depr in an envelope addressed to: Commission	osited with the U.S. Postal Service on er for Patents, P.O. Box 1450,

Signature:

04/23/2007 01 FC:2814